CD274 and neoplasm: TME remodeling in vivo. Enhanced immunotherapy activity of anti-PD-L1. ~90% of drug released after 24 h at acidic pH (50% at pH 7.4). Increased antiproliferative and apoptotic activity of encapsulated drug. Improved tumor accumulation and antitumor activity when compared with FA-free formulation.